IgA Nephropathy Clinical Trial
Official title:
IgA Nephropathy Registration Initiative of High Quality (INSIGHT)
The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure (ESRD, defined as initiation of dialysis or kidney transplantation) of IgAN patients will be compared using the IgAN database.
The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients, and developing a IgAN database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ESRD, and lab measurements of serum and urine), complications, drug information at the baseline will be collected. Patients will be follow-up every one year, the demographic and clinical characteristics, complications and drug information of patients will be collected at each visit. The investigators also record the clinical events at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), ESRD (defined as initiation of dialysis or kidney transplantation) and hospitalization for any cause. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and ESRD for IgAN patients will be compared using the IgAN database. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05016323 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
|
Phase 2 | |
Withdrawn |
NCT02433236 -
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT02231125 -
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy
|
Phase 4 | |
Completed |
NCT01502579 -
An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data
|
N/A | |
Not yet recruiting |
NCT01203007 -
Diet Intervention in Food Sensitive Patients With IgA Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00657059 -
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
|
Phase 3 | |
Recruiting |
NCT04684745 -
Open-Label Extension Study of BION-1301 in IgA Nephropathy
|
Phase 2 | |
Completed |
NCT03719443 -
First in Human Study to Assess Safety of VIS649 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02112838 -
Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy
|
Phase 2 | |
Withdrawn |
NCT02052219 -
BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
|
Phase 3 | |
Completed |
NCT00767221 -
Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study
|
Phase 2 | |
Recruiting |
NCT04438603 -
The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Terminated |
NCT04905212 -
A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy
|
Phase 2 | |
Terminated |
NCT04042623 -
Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
|
Phase 2 | |
Recruiting |
NCT03633864 -
Fecal Microbiota Transplantation for Refractory IgA Nephropathy
|
Phase 2 | |
Not yet recruiting |
NCT06454110 -
Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 | |
Recruiting |
NCT02954419 -
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
|
||
Completed |
NCT01224028 -
A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients
|
Phase 2 |